MedPath

TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis

Phase 3
Completed
Conditions
Pulmonary Tuberculosis
Registration Number
NCT00023335
Lead Sponsor
Centers for Disease Control and Prevention
Brief Summary

Primary Objective: To compare, at the completion of the follow-up phase, the clinical and bacteriologic relapse rates associated with the two study regimens.

Secondary Objectives:

To compare the clinical and bacteriologic failure rates of the two study regimens at the completion of the study phase therapy.

To compare the clinical and bacteriologic response rates for the two study regimens among patients who began study phase therapy with signs and symptoms of tuberculosis or cultures positive for M. tuberculosis.

To compare the toxicity associated with the two study regimens by comparing discontinuation rates due to adverse events and occurrence rates of signs and symptoms associated with adverse events during study phase therapy.

To compare mortality rates of the two study regimens. To compare the rates of completion of therapy within 22 weeks for the two study regimens.

To compare the rate of development of drug-resistant tuberculosis in the two study regimens among study patients classified as treatment failures or relapses.

To compare all of the above performance characteristics for the two study regimens in a small subset of HIV seropositive patients.

To compare attitudes and beliefs about participation in this study between patients who complete study therapy and those who fail to complete study therapy.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1000
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (23)

Central Arkansas Veterans Health System

🇺🇸

Little Rock, Arkansas, United States

LA County/USC Medical Center

🇺🇸

Los Angeles, California, United States

University of California, San Francisco

🇺🇸

San Francisco, California, United States

Denver Department of Public Health and Hospitals

🇺🇸

Denver, Colorado, United States

Washington, D.C. VAMC

🇺🇸

Washington, District of Columbia, United States

Chicago VA Medical Center (Lakeside)

🇺🇸

Chicago, Illinois, United States

Hines VA Medical Center

🇺🇸

Hines, Illinois, United States

Johns Hopkins University School of Medicine

🇺🇸

Baltimore, Maryland, United States

Boston Medical Center

🇺🇸

Boston, Massachusetts, United States

New Jersey Medical School

🇺🇸

Newark, New Jersey, United States

Scroll for more (13 remaining)
Central Arkansas Veterans Health System
🇺🇸Little Rock, Arkansas, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.